Q2 2023 Holdings
Filed 2023-08-10 | 166 holdings | $2.6B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Amgen Inc.(AMGN) | Common | 031162100 | $136.9M | 616,539 | 5.4% |
| Johnson & Johnson(JNJ) | Common | 478160104 | $119.5M | 721,779 | 4.7% |
| Gilead Sciences, Inc.(GILD) | Common | 375558103 | $118.2M | 1,533,884 | 4.6% |
| Regeneron Pharmaceuticals, Inc.(REGN) | Common | 75886F107 | $116.0M | 161,418 | 4.5% |
| Vertex Pharmaceuticals Inc.(VRTX) | Common | 92532F100 | $111.9M | 318,043 | 4.4% |
| Eli Lilly and Company(LLY) | Common | 532457108 | $100.1M | 213,352 | 3.9% |
| Unitedhealth Group Inc.(UNH) | Common | 91324P102 | $99.5M | 206,961 | 3.9% |
| Merck & Co., Inc.(MRK) | Common | 58933Y105 | $84.0M | 728,154 | 3.3% |
| AbbVie Inc.(ABBV) | Common | 00287Y109 | $73.5M | 545,629 | 2.9% |
| Biogen Inc.(BIIB) | Common | 09062X103 | $70.6M | 247,943 | 2.8% |
| AstraZeneca PLC(AZN) | Sponsored ADR | 046353108 | $69.9M | 976,676 | 2.7% |
| Illumina, Inc.(ILMN) | Common | 452327109 | $63.2M | 336,979 | 2.5% |
| Abbott Laboratories(ABT) | Common | 002824100 | $60.2M | 552,455 | 2.4% |
| Pfizer Inc.(PFE) | Common | 717081103 | $59.6M | 1,624,476 | 2.3% |
| Thermo Fisher Scientific Inc.(TMO) | Common | 883556102 | $51.6M | 98,987 | 2.0% |
| Elevance Health, Inc.(ELV) | Common | 036752103 | $50.7M | 114,070 | 2.0% |
| Moderna, Inc.(MRNA) | Common | 60770K107 | $41.8M | 343,695 | 1.6% |
| Boston Scientific Corp.(BSX) | Common | 101137107 | $35.6M | 657,790 | 1.4% |
| Danaher Corp.(DHR) | Common | 235851102 | $34.3M | 142,813 | 1.3% |
| Medtronic plc(MDT) | Shares | G5960L103 | $30.3M | 344,417 | 1.2% |
| Idexx Laboratories, Inc.(IDXX) | Common | 45168D104 | $29.4M | 58,595 | 1.2% |
| Dexcom, Inc.(DXCM) | Common | 252131107 | $29.4M | 228,747 | 1.2% |
| Bristol-Myers Squibb Company(BMY) | Common | 110122108 | $29.3M | 458,498 | 1.1% |
| Intuitive Surgical, Inc.(ISRG) | Common | 46120E602 | $28.7M | 83,980 | 1.1% |
| Alnylam Pharmaceuticals, Inc.(ALNY) | Common | 02043Q107 | $27.2M | 143,214 | 1.1% |
| The Cigna Group(CI) | Common | 125523100 | $27.0M | 96,339 | 1.1% |
| McKesson Corp.(MCK) | Common | 58155Q103 | $26.5M | 61,955 | 1.0% |
| argenx SE(ARGX) | Sponsored ADR | 04016X101 | $25.5M | 65,553 | 1.0% |
| HCA Healthcare, Inc.(HCA) | Common | 40412C101 | $25.0M | 82,403 | 1.0% |
| Stryker Corp.(SYK) | Common | 863667101 | $24.8M | 81,128 | 1.0% |
| Iqvia Holdings Inc.(IQV) | Common | 46266C105 | $24.5M | 109,129 | 1.0% |
| Zoetis Inc.(ZTS) | Class A | 98978V103 | $23.6M | 136,914 | 0.9% |
| Charles River Laboratories International, Inc.(CRL) | Common | 159864107 | $23.4M | 111,183 | 0.9% |
| Seagen Inc.(SGENUSD) | Common | 81181C104 | $21.6M | 112,331 | 0.8% |
| Sarepta Therapeutics, Inc.(SRPT) | Common | 803607100 | $20.5M | 179,437 | 0.8% |
| Novo Nordisk A/S(NVO) | Sponsored ADR | 670100205 | $19.9M | 122,777 | 0.8% |
| Oculis Holding AG | Common | 952KVL905 | $18.8M | 1,690,741 | 0.7% |
| Molina Healthcare, Inc.(MOH) | Common | 60855R100 | $18.6M | 61,856 | 0.7% |
| Jazz Pharmaceuticals plc(JAZZ) | Shares | G50871105 | $18.3M | 147,779 | 0.7% |
| BioMarin Pharmaceutical Inc.(BMRN) | Common | 09061G101 | $18.3M | 210,789 | 0.7% |
| Edwards Lifesciences Corp.(EW) | Common | 28176E108 | $17.9M | 189,597 | 0.7% |
| Humana Inc.(HUM) | Common | 444859102 | $16.5M | 36,794 | 0.6% |
| Apellis Pharmaceuticals, Inc.(APLS) | Common | 03753U106 | $15.8M | 173,248 | 0.6% |
| Baxter International, Inc.(BAX) | Common | 071813109 | $14.8M | 324,370 | 0.6% |
| Exelixis, Inc.(EXEL) | Common | 30161Q104 | $13.9M | 726,639 | 0.5% |
| Novartis AG(NVSN) | Sponsored ADR | 66987V109 | $13.7M | 136,225 | 0.5% |
| Karuna Therapeutics, Inc. | Common | 48576A100 | $12.7M | 58,577 | 0.5% |
| Insulet Corp.(PODD) | Common | 45784P101 | $12.6M | 43,847 | 0.5% |
| Guardant Health, Inc.(GH) | Common | 40131M109 | $12.4M | 346,084 | 0.5% |
| Ascendis Pharma A/S(ASND) | Sponsored ADR | 04351P101 | $12.4M | 138,791 | 0.5% |